Not provided
Not provided
Not provided
Not provided
Great difficulties were encountered during recruitment, for fear Denozumab. Only 2 patients have been included since the study start.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| University Hospital, Lille | OTHER |
| Nantes University Hospital | OTHER |
| University Hospital, Paris | OTHER |
| University Hospital, Rouen |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The drastic reduction of nutritional intake in anorexia nervosa(AN) alters many hormonal factors that regulate the activity of bone cells. This alteration of bone remodeling is characterized by increased bone resorption and decreased bone formation, leading to a marked reduction of bone mineral density, osteoporosis and an increased risk of fracture.
To date, there is a paucity of studies and no consensus on the management of bone loss in patients with AN. The few previous studies were performed with small samples and using short follow-up periods.
Denosumab is a fully human monoclonal antibody that binds with high specificity to human RANKL (6, 7), thereby reducing the number and activity of osteoclasts and therefore decreasing bone resorption that was found increased in patients AN.
Denosumab may transiently protect bone whilst psychonutritional management will induce a weight restoration
The project propose to assess, with a double-blind multicentric randomized clinical trial, the effects of Denosumab on bone mineral density (BMD) change at lumbar spine over 12 months among patients suffering from an acute anorexia nervosa (AN).
84 patients suffering from a current anorexia nervosa with an evidence of low BMD determined by a Z-score value < -2 DS at least one site (lumbar spine or total proximal femur) will be recruit .
Eligible patients will be randomized into two groups: denosumab versus placebo. Each patient will attend a total of 8 scheduled visits, which will be completed over a period of 24 months +/- 15days from screening visit to end of study (inclusion, 10 days, and 3, 6, 12, 15, 18, & 24 months).
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Denosumab subcutaneous injections | Active Comparator | The treated group (n = 42) will receive Denosumab (60 mg, two subcutaneous injections at M0 and M6) associated with a daily treatment of vitamin D (800 IU) + calcium (1000 mg). |
|
| Placebo subcutaneous injections | Placebo Comparator | The control group (n = 42) will received a placebo injection (two subcutaneous injections at M0 and M6) with daily treatment of vitamin D (800 IU) +calcium (1000 mg). |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Denosumab subcutaneous injections | Drug | Subcutaneous injection of Denosumab 60 mg, one injection at baseline and another injection at 6 months |
|
| Measure | Description | Time Frame |
|---|---|---|
| Value of bone mineral density in lumbar spine (g/cm2) | Comparison of bone mineral density changes in the lumbar spine at M12 between groups with Denosumab and placebo after two injections either of Denosumab or placebo. Bone mineral density is objectified by the Z-score obtained by bone mineral density. | 12 months |
| Measure | Description | Time Frame |
|---|---|---|
| value of bone mineral density in the whole body, the total proximal femur and the radius (g/cm2) | Comparison of bone mineral density changes in the whole body, the total proximal femur and the radius between groups at M12 after two injections of Denosumab. | 12 months |
| values of bone mineral density at 24 months |
Not provided
Inclusion criteria:
Patients with a current AN defined by DSM-V criteria
Being female
Age over or equal to 18 years and less or equal to 40 years
. For patients under 20 years of age, effective bone maturation (attested by a radiography of the hip)
Agree to take contraception up to five months after the last injection of denosumab .
Absence of pregnancy evidenced by an interview and a negative assay of human chorionic gonadotropin (ßhCG).
Evidence of low BMD determined by Z-score value < -2 DS (at least one site (lumbar spine or total proximal femur)
Signing an informed consent.
Exclusion criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Sébastien Guillaume, MD PhD | Hôpital Lapeyronie - CHU de Montpellier | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| CHU Montpellier | Montpellier | 34295 | France |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000856 | Anorexia Nervosa |
| ID | Term |
|---|---|
| D001068 | Feeding and Eating Disorders |
| D001523 | Mental Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| D035061 | Control Groups |
| ID | Term |
|---|---|
| D015340 | Epidemiologic Research Design |
| D004812 | Epidemiologic Methods |
| D008919 | Investigative Techniques |
| D012107 | Research Design |
Not provided
Not provided
| OTHER |
Not provided
Not provided
Not provided
Not provided
|
| Placebo subcutaneous injections | Drug | Subcutaneous injection of Placebo, one injection at baseline and another injection at 6 months |
|
|
Comparison of the levels of bone mineral density at 24 months |
| 24 months |
| values of bone remodeling markers at 24 months | Comparison of the values of bone remodeling markers at 24 months | 24 months |
| links between ESR1 genotype and bone minéral density at Baseline and response to Denosunab | Assess the links between ESR1 genotype and BMD at baseline and response to Denosunab (variation of BMD between baseline and 12 months). | 12 months |
| D008722 | Methods |